• Utah Medical Products reported 1Q 2026 net income of USD 2.6 million, down 14.4%, with diluted EPS of USD 0.818, down 11%.
• Net sales fell 10.2% to USD 8.7 million, while operating income dropped 18.7% to USD 2.6 million.
• Gross profit margin widened 3.6 percentage points to 60.6%, but operating income margin narrowed 3.1 percentage points to 29.4%.
• Management said 1Q results were consistent with 2026 projections following loss of largest China distributor for blood pressure monitoring devices in 3Q 2025.
• 2026 objectives include new sales of high-pressure process control transducer configurations, regaining outside-US business, and substantially concluding Filshie Clip System product liability lawsuits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Utah Medical Products Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001096906-26-000767), on May 12, 2026, and is solely responsible for the information contained therein.